Leerink Partnrs Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a hold rating in a research report released on Tuesday, Zacks.com reports.

REGN has been the subject of several other research reports. Canaccord Genuity Group reissued a buy rating and set a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Cantor Fitzgerald reiterated a neutral rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, September 16th. TD Cowen increased their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a research note on Tuesday, July 23rd. BMO Capital Markets reissued an outperform rating and issued a $1,300.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an overweight rating for the company in a research note on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of Moderate Buy and an average price target of $1,118.62.

Regeneron Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ REGN opened at $1,039.96 on Tuesday. The stock has a market capitalization of $114.59 billion, a P/E ratio of 30.72, a PEG ratio of 3.72 and a beta of 0.12. Regeneron Pharmaceuticals has a 52-week low of $769.19 and a 52-week high of $1,211.20. The stock’s 50 day moving average price is $1,129.87 and its two-hundred day moving average price is $1,033.99. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The company had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the prior year, the company earned $8.79 earnings per share. The business’s revenue was up 12.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Gilbert & Cook Inc. increased its position in Regeneron Pharmaceuticals by 8.3% in the 4th quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock worth $1,675,000 after purchasing an additional 146 shares during the last quarter. TrinityPoint Wealth LLC increased its holdings in Regeneron Pharmaceuticals by 4.8% in the fourth quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 12 shares during the last quarter. D.A. Davidson & CO. increased its holdings in Regeneron Pharmaceuticals by 17.0% in the fourth quarter. D.A. Davidson & CO. now owns 709 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 103 shares during the last quarter. US Bancorp DE raised its position in Regeneron Pharmaceuticals by 6.7% during the fourth quarter. US Bancorp DE now owns 4,941 shares of the biopharmaceutical company’s stock valued at $4,340,000 after acquiring an additional 310 shares in the last quarter. Finally, Congress Wealth Management LLC DE acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $271,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.